Molecular Partners AG, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of various biopharmaceutical products.
The last earnings update was 38 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Molecular Partners. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Molecular Partners's earnings available for a low price, and how does
this compare to other companies in the same industry?
Molecular Partners's earnings are expected to grow significantly at over 20% yearly.
Molecular Partners's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Molecular Partners's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Molecular Partners's finances.
The net worth of a company is the difference between its assets and liabilities.
Molecular Partners is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Molecular Partners's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Molecular Partners's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Molecular Partners has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Patrick Amstutz, Ph.D. is a Co-Founder of Molecular Partners AG and has been its Chief Executive Officer since November 2016 and serves as its Member of Management Board. Dr. Amstutz served as Acting Chief Executive Officer of Molecular Partners AG since November 7, 2016. Dr. Amstutz served as the Chief Operating Officer of Molecular Partners AG. since 2014 until November 7, 2016. Dr. Amstutz served as Chief Business Officer of Molecular Partners AG from 2006 to 2014. He has been a Director of Molecular Partners AG since October 31, 2017. He was responsible for the achievement of full freedom to operate by licensing several key technologies and now oversees business development and strategic Partnering. During his work at Molecular Partners, he has established a whole range of fruitful commercial and academic collaborations. He holds a master of science from the ETH and earned his PhD at the University of Zurich.
Patrick's compensation has increased whilst company is loss making.
Patrick's remuneration is about average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Molecular Partners management team is about average.
CFO & Member of Management Board
Chief Medical Officer & Member of Management Board
Chief Scientific Officer & Member of Management Board
Vice President of Technology
Vice President of Finance
Vice President of Human Resources
Senior Vice President of Development
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Molecular Partners board of directors is less than 3 years, this suggests a new board.
Molecular Partners AG, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of various biopharmaceutical products. It is developing Abicipar, a DARPin-based anti-angiogenic drug, which is in Phase III clinical trials for the treatment of wet age-related macular degeneration and diabetic macular edema diseases, as well as on a partnered pipeline that includes novel approaches to the treatment of severe ocular diseases. The company also develops MP0250, which is in Phase I clinical studies for the treatment of solid tumor cancers and hematological malignancies; and MP0274 that is in preclinical studies for the treatment of breast cancer. The company has strategic partnerships with Allergan, Inc.; Janssen Biotech, Inc.; and Amgen SA. Molecular Partners AG was founded in 2004 and is based in Schlieren, Switzerland.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.